| Year |
Citation |
Score |
| 2019 |
Ryan KM, Boyle NT, Harkin A, Connor TJ. Dexamethasone attenuates inflammatory-mediated suppression of β-adrenoceptor expression in rat primary mixed glia. Journal of Neuroimmunology. 338: 577082. PMID 31707103 DOI: 10.1016/J.Jneuroim.2019.577082 |
0.309 |
|
| 2019 |
Ryan KM, Allers KA, McLoughlin DM, Harkin A. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy. Brain, Behavior, and Immunity. PMID 31606477 DOI: 10.1016/J.Bbi.2019.10.005 |
0.329 |
|
| 2019 |
Dempsey E, Abautret-Daly Á, Docherty NG, Medina C, Harkin A. Persistent Central Inflammation and Region Specific Cellular Activation Accompany Depression- and Anxiety-like Behaviours During the Resolution Phase of Experimental Colitis. Brain, Behavior, and Immunity. PMID 31063848 DOI: 10.1016/J.Bbi.2019.05.007 |
0.393 |
|
| 2019 |
O'Neill E, Chiara Goisis R, Haverty R, Harkin A. L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats. Journal of Neuroscience Research. PMID 30924171 DOI: 10.1002/Jnr.24420 |
0.333 |
|
| 2019 |
David J, Gormley S, McIntosh AL, Kebede V, Thuery G, Varidaki A, Coffey ET, Harkin A. L-alpha-amino adipic acid provokes depression-like behaviour and a stress related increase in dendritic spine density in the pre-limbic cortex and hippocampus in rodents. Behavioural Brain Research. PMID 30639510 DOI: 10.1016/J.Bbr.2019.01.015 |
0.374 |
|
| 2018 |
Finnegan M, Galligan T, Ryan K, Shanahan E, Harkin A, Daly L, McLoughlin DM. Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy: A Randomized Controlled Pilot Trial. The Journal of Ect. PMID 30531397 DOI: 10.1097/Yct.0000000000000560 |
0.303 |
|
| 2018 |
Harkin A, McLoughlin DM. Ketamine and depression: A special kase for kynurenic acid? Brain, Behavior, and Immunity. PMID 30399405 DOI: 10.1016/J.Bbi.2018.11.004 |
0.313 |
|
| 2018 |
David J, O'Toole E, O'Reilly K, Thuery G, Assmann N, Finlay D, Harkin A. Inhibitors of the NMDA-nitric Oxides Signaling Pathway Protect Against Neuronal Atrophy and Synapse Loss Provoked by l-alpha Aminoadipic Acid-treated Astrocytes. Neuroscience. PMID 30267830 DOI: 10.1016/J.Neuroscience.2018.09.023 |
0.319 |
|
| 2018 |
Farrell C, Doolin K, O' Leary N, Jairaj C, Roddy D, Tozzi L, Morris D, Harkin A, Frodl T, Nemoda Z, Szyf M, Booij L, O'Keane V. DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic-pituitary-adrenal axis activity and to early life emotional abuse. Psychiatry Research. 265: 341-348. PMID 29793048 DOI: 10.1016/J.Psychres.2018.04.064 |
0.312 |
|
| 2018 |
Doolin K, Allers KA, Pleiner S, Liesener A, Farrell C, Tozzi L, O'Hanlon E, Roddy D, Frodl T, Harkin A, O'Keane V. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes. Psychoneuroendocrinology. 95: 8-17. PMID 29787958 DOI: 10.1016/J.Psyneuen.2018.05.019 |
0.351 |
|
| 2018 |
Yssel JD, O'Neill E, Nolan YM, Connor TJ, Harkin A. Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease. Brain, Behavior, and Immunity. PMID 29339319 DOI: 10.1016/J.Bbi.2018.01.004 |
0.345 |
|
| 2018 |
Griffin ÉW, Yssel JD, O'Neill E, Ryan KJ, Boyle N, Harper P, Harkin A, Connor T. The β2-adrenoceptor agonist clenbuterol reduces the neuroinflammatory response, neutrophil infiltration and apoptosis following intra-striatal IL-1β administration to rats. Immunopharmacology and Immunotoxicology. 1-8. PMID 29303018 DOI: 10.1080/08923973.2017.1418882 |
0.314 |
|
| 2018 |
O'Reilly K, David J, Harkin A. ZL006 has antidepressant effects and attenuates changes in dendritic spines associated with astrocytic impairment in mice European Neuropsychopharmacology. 28. DOI: 10.1016/J.Euroneuro.2017.12.071 |
0.405 |
|
| 2017 |
Doolin K, Farrell C, Tozzi L, Harkin A, Frodl T, O'Keane V. Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder. International Journal of Molecular Sciences. 18. PMID 29064428 DOI: 10.3390/Ijms18102226 |
0.321 |
|
| 2017 |
Sherwin E, Lennon A, Harkin A. Regional Specific Modulation of Stress-Induced Neuronal Activation Associated with the PSD95/NOS Interaction Inhibitor ZL006 in the Wistar Kyoto Rat. The International Journal of Neuropsychopharmacology. 20: 833-843. PMID 28977524 DOI: 10.1093/Ijnp/Pyx053 |
0.335 |
|
| 2017 |
O'Farrell K, Fagan E, Connor TJ, Harkin A. Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons. European Journal of Pharmacology. PMID 28688912 DOI: 10.1016/J.Ejphar.2017.07.008 |
0.353 |
|
| 2017 |
McIntosh AL, Gormley S, Tozzi L, Frodl T, Harkin A. Recent Advances in Translational Magnetic Resonance Imaging in Animal Models of Stress and Depression. Frontiers in Cellular Neuroscience. 11: 150. PMID 28596724 DOI: 10.3389/Fncel.2017.00150 |
0.301 |
|
| 2017 |
Abautret-Daly Á, Dempsey E, Parra-Blanco A, Medina C, Harkin A. Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. Acta Neuropsychiatrica. 1-22. PMID 28270247 DOI: 10.1017/Neu.2017.3 |
0.317 |
|
| 2017 |
McLoughlin D, Finnegan M, Ryan K, Shanahan E, Harkin A, Daly L. The KEEP-WELL trial (NCT02414932) – ketamine for depression relapse prevention following ECT European Neuropsychopharmacology. 27. DOI: 10.1016/S0924-977X(17)31035-0 |
0.304 |
|
| 2016 |
Finnegan M, Ryan K, Shanahan E, Harkin A, Daly L, McLoughlin DM. Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial). Pilot and Feasibility Studies. 2: 38. PMID 27965856 DOI: 10.1186/S40814-016-0080-0 |
0.345 |
|
| 2016 |
Sherwin E, Gigliucci V, Harkin A. Regional specific modulation of neuronal activation associated with nitric oxide synthase inhibitors in an animal model of antidepressant activity. Behavioural Brain Research. 316: 18-28. PMID 27569181 DOI: 10.1016/J.Bbr.2016.08.049 |
0.342 |
|
| 2016 |
O'Neill E, Kwok B, Day JS, Connor TJ, Harkin A. Amitriptyline protects against TNF-α-induced atrophy and reduction in synaptic markers via a Trk-dependent mechanism. Pharmacology Research & Perspectives. 4: e00195. PMID 27069625 DOI: 10.1002/Prp2.195 |
0.343 |
|
| 2016 |
Gormley S, Rouine J, McIntosh A, Kerskens C, Harkin A. Glial fibrillary acidic protein (GFAP) immunoreactivity correlates with cortical perfusion parameters determined by bolus tracking arterial spin labelling (bt-ASL) magnetic resonance (MR) imaging in the Wistar Kyoto rat. Physiology & Behavior. PMID 27068181 DOI: 10.1016/J.Physbeh.2016.04.007 |
0.348 |
|
| 2016 |
Ryan KM, Griffin ÉW, Ryan KJ, Tanveer R, Vanattou-Saifoudine N, McNamee EN, Fallon E, Heffernan S, Harkin A, Connor TJ. Clenbuterol activates the central IL-1 system via the β2-adrenoceptor without provoking inflammatory response related behaviours in rats. Brain, Behavior, and Immunity. PMID 26928198 DOI: 10.1016/J.Bbi.2016.02.023 |
0.356 |
|
| 2016 |
Hughes MM, Connor TJ, Harkin A. Stress-related immune markers in depression: implications for treatment. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). PMID 26775294 DOI: 10.1093/Ijnp/Pyw001 |
0.349 |
|
| 2016 |
McIntosh A, Gormley S, Harkin A. P.4.019 Disrupting astrocyte function in the prelimbic cortex induces a depressive-like phenotype and alters cerebral perfusion European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)70109-X |
0.346 |
|
| 2016 |
David J, McIntosh A, Harkin A. P.4.011 L-α-Aminoadipic acid provokes a reduction of astrocytes in the prelimbic cortex and depressive-like behaviour in mice European Neuropsychopharmacology. 26. DOI: 10.1016/S0924-977X(16)70101-5 |
0.337 |
|
| 2015 |
Morgese MG, Colaianna M, Mhillaj E, Zotti M, Schiavone S, D'Antonio P, Harkin A, Gigliucci V, Campolongo P, Trezza V, De Stradis A, Tucci P, Cuomo V, Trabace L. Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1. Frontiers in Neuroscience. 9: 428. PMID 26594145 DOI: 10.3389/Fnins.2015.00428 |
0.325 |
|
| 2015 |
Doucet MV, O'Toole E, Connor T, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface protect against glutamate-induced neuronal atrophy in primary cortical neurons. Neuroscience. 301: 421-38. PMID 26071957 DOI: 10.1016/J.Neuroscience.2015.06.004 |
0.321 |
|
| 2015 |
Murray C, Griffin ÉW, O'Loughlin E, Lyons A, Sherwin E, Ahmed S, Stevenson NJ, Harkin A, Cunningham C. Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C. Brain, Behavior, and Immunity. 48: 274-86. PMID 25900439 DOI: 10.1016/J.Bbi.2015.04.009 |
0.301 |
|
| 2015 |
McIntosh A, Gormley S, Harkin A. P.2.a.013 Altered astrocyte function in the pre-limbic cortex and amygdala induces an anxiety and depressive-like phenotype in adult rats European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30497-1 |
0.351 |
|
| 2014 |
Harkin A. Muscling in on depression. The New England Journal of Medicine. 371: 2333-4. PMID 25494274 DOI: 10.1056/Nejmcibr1411568 |
0.301 |
|
| 2014 |
Gigliucci V, Gormley S, Gibney S, Rouine J, Kerskens C, Connor TJ, Harkin A. Characterisation of the antidepressant properties of nitric oxide synthase inhibitors in the olfactory bulbectomised rat model of depression. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1349-61. PMID 24931298 DOI: 10.1016/J.Euroneuro.2014.05.003 |
0.358 |
|
| 2014 |
O'Donovan S, Dalton V, Harkin A, McLoughlin DM. Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 17: 1477-86. PMID 24607259 DOI: 10.1017/S1461145714000200 |
0.368 |
|
| 2014 |
Gibney SM, Fagan EM, Waldron AM, O'Byrne J, Connor TJ, Harkin A. Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 17: 917-28. PMID 24472498 DOI: 10.1017/S1461145713001673 |
0.38 |
|
| 2014 |
Day JS, O'Neill E, Cawley C, Aretz NK, Kilroy D, Gibney SM, Harkin A, Connor TJ. Noradrenaline acting on astrocytic β₂-adrenoceptors induces neurite outgrowth in primary cortical neurons. Neuropharmacology. 77: 234-48. PMID 24126345 DOI: 10.1016/J.Neuropharm.2013.09.027 |
0.301 |
|
| 2014 |
Maria NI, Helden-Meeuwsen CGv, Brkic Z, Daele PLv, Hagen Mv, Gibney SM, Harkin A, Drexhage HA, Versnel MA. AB0186 Elevated Indoleamine-2,3-Dioxygenase (IDO) and Tryptophan Catabolism in Primary SjÖGren's Syndrome Patients, Positive for the Interferon Type I Signature: A Possible Link to Fatigue and Depression Annals of the Rheumatic Diseases. 73: 864-864. DOI: 10.1136/Annrheumdis-2014-Eular.3725 |
0.314 |
|
| 2014 |
O'toole E, Doucet M, Harkin A. Astrocytic dysfunction induced by l-alphaaminoadipic acid reduces measures of neuronal complexity in vitro; rescue by NMDA receptor antagonists Journal of Neuroimmunology. 275: 127-128. DOI: 10.1016/J.Jneuroim.2014.08.341 |
0.313 |
|
| 2014 |
Gormley S, Kerskens C, Harkin A. 106. Reduced cortical astroglial cell numbers coupled to reduced cortical cerebral blood perfusion in a genetically predisposed model of depression as assessed by magnetic resonance bolus tracking arterial spin labelling (MR-btASL) Brain, Behavior, and Immunity. 40: e31. DOI: 10.1016/J.Bbi.2014.06.126 |
0.32 |
|
| 2014 |
Sherwin E, Gormley S, McGuinness B, Harkin A. 105. Enhanced glucocorticoid sensitivity coupled with reduced microglial activation in a genetically predisposed animal model of depression Brain, Behavior, and Immunity. 40: e31. DOI: 10.1016/J.Bbi.2014.06.125 |
0.321 |
|
| 2013 |
Pertl MM, Hevey D, Boyle NT, Hughes MM, Collier S, O'Dwyer AM, Harkin A, Kennedy MJ, Connor TJ. C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain, Behavior, and Immunity. 34: 108-19. PMID 23928287 DOI: 10.1016/J.Bbi.2013.07.177 |
0.351 |
|
| 2013 |
Ryan KJ, Griffin É, Yssel JD, Ryan KM, McNamee EN, Harkin A, Connor TJ. Stimulation of central β2-adrenoceptors suppresses NFκB activity in rat brain: a role for IκB. Neurochemistry International. 63: 368-78. PMID 23896303 DOI: 10.1016/J.Neuint.2013.07.006 |
0.312 |
|
| 2013 |
Gigliucci V, O'Dowd G, Casey S, Egan D, Gibney S, Harkin A. Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology. 228: 157-66. PMID 23455595 DOI: 10.1007/S00213-013-3024-X |
0.333 |
|
| 2013 |
Doucet MV, Levine H, Dev KK, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1575-84. PMID 23446451 DOI: 10.1038/Npp.2013.57 |
0.377 |
|
| 2013 |
Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain, Behavior, and Immunity. 28: 170-81. PMID 23201589 DOI: 10.1016/J.Bbi.2012.11.010 |
0.389 |
|
| 2013 |
Ryan K, Harkin A, McLoughlin D. 116. The hippocampal miRNome in the chronic corticosterone model of depression Brain, Behavior, and Immunity. 32: e33-e34. DOI: 10.1016/J.Bbi.2013.07.128 |
0.366 |
|
| 2012 |
Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, Steiner J, Connor TJ, Harkin A, Versnel MA, Drexhage HA. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology. 92: 959-75. PMID 22875882 DOI: 10.1189/Jlb.0212100 |
0.338 |
|
| 2012 |
Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T, Connor TJ. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain, Behavior, and Immunity. 26: 979-87. PMID 22683764 DOI: 10.1016/J.Bbi.2012.05.010 |
0.374 |
|
| 2012 |
Doucet MV, Harkin A, Dev KK. The PSD-95/nNOS complex: new drugs for depression? Pharmacology & Therapeutics. 133: 218-29. PMID 22133842 DOI: 10.1016/J.Pharmthera.2011.11.005 |
0.357 |
|
| 2012 |
Vanattou-Saïfoudine N, Behan B, Harkin A. Dopamine D1 receptor-mediated intracellular responses in the hypothalamus after co-administration of caffeine with MDMA. Basic & Clinical Pharmacology & Toxicology. 110: 283-9. PMID 21967278 DOI: 10.1111/J.1742-7843.2011.00805.X |
0.322 |
|
| 2011 |
Gibney S, McGuinness B, Prendergast C, Harkin A, Connor T. 149. Poly I:C-induced activation of the innate immune response is accompanied by symptoms of depression and anxiety Brain, Behavior, and Immunity. 25: S222. DOI: 10.1016/J.Bbi.2011.07.152 |
0.315 |
|
| 2010 |
Gleeson LC, Ryan KJ, Griffin EW, Connor TJ, Harkin A. The β2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity. Brain, Behavior, and Immunity. 24: 1354-61. PMID 20599496 DOI: 10.1016/J.Bbi.2010.06.015 |
0.374 |
|
| 2010 |
Vanattou-Saïfoudine N, McNamara R, Harkin A. Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats British Journal of Pharmacology. 160: 860-877. PMID 20590585 DOI: 10.1111/J.1476-5381.2010.00660.X |
0.314 |
|
| 2010 |
McNamee EN, Ryan KM, Griffin EW, González-Reyes RE, Ryan KJ, Harkin A, Connor TJ. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain, Behavior, and Immunity. 24: 660-71. PMID 20193756 DOI: 10.1016/J.Bbi.2010.02.005 |
0.345 |
|
| 2010 |
O'Sullivan JB, Ryan KM, Harkin A, Connor TJ. Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. Journal of Neuroimmunology. 220: 34-42. PMID 20061033 DOI: 10.1016/J.Jneuroim.2009.12.007 |
0.324 |
|
| 2010 |
Gigliucci V, Buckley KN, Nunan J, O'Shea K, Harkin A. A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test. Pharmacology, Biochemistry, and Behavior. 94: 524-33. PMID 19945477 DOI: 10.1016/J.Pbb.2009.11.007 |
0.324 |
|
| 2010 |
Beumer W, Abautret-daly A, Helden-Meeuwsen CGv, Harkin A, Drexhage H, Versnel MA. The NOD mouse model for immune induced depressive-like behavior Brain Behavior and Immunity. 24. DOI: 10.1016/J.Bbi.2010.07.168 |
0.32 |
|
| 2009 |
O'Sullivan JB, Ryan KM, Curtin NM, Harkin A, Connor TJ. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 12: 687-99. PMID 19046481 DOI: 10.1017/S146114570800967X |
0.353 |
|
| 2008 |
Durkin S, Prendergast A, Harkin A. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats Progress in Neuro-Psychopharmacology and Biological Psychiatry. 32: 1894-1901. PMID 18824064 DOI: 10.1016/J.Pnpbp.2008.09.008 |
0.348 |
|
| 2008 |
Connor TJ, Starr N, O'Sullivan JB, Harkin A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma? Neuroscience Letters. 441: 29-34. PMID 18584961 DOI: 10.1016/J.Neulet.2008.06.007 |
0.326 |
|
| 2008 |
McNamee EN, González-Reyes RE, Harkin A, Connor TJ. 125. Pharmacological enhancement of central noradrenergic tone induces IL-10 production and signalling in rat brain: A role for β-adrenoceptor activation Brain Behavior and Immunity. 22: 40. DOI: 10.1016/J.Bbi.2008.04.127 |
0.304 |
|
| 2007 |
Roche M, Harkin A, Kelly JP. Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1312-20. PMID 17119540 DOI: 10.1038/Sj.Npp.1301253 |
0.365 |
|
| 2006 |
McNamara R, Kerans A, O'Neill B, Harkin A. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love") Neuropharmacology. 50: 69-80. PMID 16188283 DOI: 10.1016/J.Neuropharm.2005.08.006 |
0.328 |
|
| 2005 |
Connor TJ, Brewer C, Kelly JP, Harkin A. Acute stress suppresses pro-inflammatory cytokines TNF-alpha and IL-1 beta independent of a catecholamine-driven increase in IL-10 production. Journal of Neuroimmunology. 159: 119-28. PMID 15652410 DOI: 10.1016/J.Jneuroim.2004.10.016 |
0.305 |
|
| 2005 |
Connor TJ, Harkin A, Kelly JP. Methylenedioxymethamphetamine suppresses production of the proinflammatory cytokine tumor necrosis factor-alpha independent of a beta-adrenoceptor-mediated increase in interleukin-10. The Journal of Pharmacology and Experimental Therapeutics. 312: 134-43. PMID 15331655 DOI: 10.1124/Jpet.104.073023 |
0.312 |
|
| 2004 |
Harkin A, Connor TJ, Burns MP, Kelly JP. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14: 274-81. PMID 15163436 DOI: 10.1016/J.Euroneuro.2003.08.010 |
0.355 |
|
| 2003 |
Harkin A, Hynes MJ, Masterson E, Kelly JP, O'Donnell JM, Connor TJ. A toxicokinetic study of nickel-induced immunosuppression in rats. Immunopharmacology and Immunotoxicology. 25: 655-70. PMID 14686805 DOI: 10.1081/Iph-120026448 |
0.306 |
|
| 2003 |
Harkin A, Shanahan E, Kelly JP, Connor TJ. Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. The European Journal of Neuroscience. 18: 1021-7. PMID 12925028 DOI: 10.1046/J.1460-9568.2003.02802.X |
0.33 |
|
| 2003 |
Harkin A, Connor TJ, Walsh M, St John N, Kelly JP. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology. 44: 616-23. PMID 12668047 DOI: 10.1016/S0028-3908(03)00030-3 |
0.357 |
|
| 2003 |
Harkin A, Kelly JP, Leonard BE. A review of the relevance and validity of olfactory bulbectomy as a model of depression Clinical Neuroscience Research. 3: 253-262. DOI: 10.1016/S1566-2772(03)00087-2 |
0.345 |
|
| 2002 |
Harkin A, Houlihan DD, Kelly JP. Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine. Journal of Psychopharmacology (Oxford, England). 16: 115-23. PMID 12095069 DOI: 10.1177/026988110201600201 |
0.31 |
|
| 2001 |
Harkin A, Connor TJ, Mulrooney J, Kelly JP, Leonard BE. Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. Life Sciences. 68: 1367-82. PMID 11388689 DOI: 10.1016/S0024-3205(00)01039-0 |
0.35 |
|
| 2001 |
Connor TJ, Dennedy MC, Harkin A, Kelly JP. Methylenedioxymethamphetamine-induced suppression of interleukin-1beta and tumour necrosis factor-alpha is not mediated by serotonin. European Journal of Pharmacology. 418: 147-52. PMID 11334877 DOI: 10.1016/S0014-2999(01)00928-1 |
0.329 |
|
| 2001 |
Harkin A, Morris K, Kelly JP, O'Donnell JM, Leonard BE. Modulation of MK-801-induced behaviour by noradrenergic agents in mice. Psychopharmacology. 154: 177-88. PMID 11314680 DOI: 10.1007/S002130000630 |
0.347 |
|
| 2000 |
Harkin A, Nally R, Kelly JP, Leonard BE. Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression. Journal of Neural Transmission (Vienna, Austria : 1996). 107: 1213-27. PMID 11129111 DOI: 10.1016/S0924-977X(00)80279-5 |
0.371 |
|
| 2000 |
Kelliher P, Connor TJ, Harkin A, Sanchez C, Kelly JP, Leonard BE. Varying responses to the rat forced-swim test under diurnal and nocturnal conditions. Physiology & Behavior. 69: 531-9. PMID 10913793 DOI: 10.1016/S0031-9384(00)00213-4 |
0.317 |
|
| 2000 |
Harkin A, Nowak G, Paul IA. Corrigendum to: "Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors" European Journal of Pharmacology. 397: 399. PMID 10844140 DOI: 10.1016/S0014-2999(00)00327-7 |
0.567 |
|
| 2000 |
Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP, Leonard BE. Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacology, Biochemistry, and Behavior. 65: 591-7. PMID 10764911 DOI: 10.1016/S0091-3057(99)00192-6 |
0.378 |
|
| 2000 |
Cryan JF, Harkin A, Naughton M, Kelly JP, Leonard BE. Characterization of D-fenfluramine-induced hypothermia: evidence for multiple sites of action. European Journal of Pharmacology. 390: 275-85. PMID 10708734 DOI: 10.1016/S0014-2999(00)00012-1 |
0.317 |
|
| 2000 |
Harkin A, Nowak G, Paul IA. Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors. European Journal of Pharmacology. 389: 187-92. PMID 10688983 DOI: 10.1016/S0014-2999(99)00923-1 |
0.608 |
|
| 2000 |
Harkin A, Kelly JP, Frawley J, O'Donnell JM, Leonard BE. Test conditions influence the response to a drug challenge in rodents. Pharmacology, Biochemistry, and Behavior. 65: 389-98. PMID 10683478 DOI: 10.1016/S0091-3057(99)00210-5 |
0.308 |
|
| 2000 |
Connor TJ, Harkin A, Kelly JP, Leonard BE. Olfactory bulbectomy provokes a suppression of interleukin-1beta and tumour necrosis factor-alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment. Neuroimmunomodulation. 7: 27-35. PMID 10601816 DOI: 10.1159/000026417 |
0.371 |
|
| 1999 |
Connor TJ, Kelliher P, Harkin A, Kelly JP, Leonard BE. Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. European Journal of Pharmacology. 379: 125-33. PMID 10497898 DOI: 10.1016/S0014-2999(99)00492-6 |
0.354 |
|
| 1999 |
Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE. Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology. 145: 303-8. PMID 10494579 DOI: 10.1007/S002130051062 |
0.403 |
|
| 1999 |
Harkin AJ, Bruce KH, Craft B, Paul IA. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. European Journal of Pharmacology. 372: 207-13. PMID 10395013 DOI: 10.1016/S0014-2999(99)00191-0 |
0.572 |
|
| 1999 |
Redmond AM, Harkin A, Kelly JP, Leonard BE. Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 9: 165-70. PMID 10082243 DOI: 10.1016/S0924-977X(98)00023-6 |
0.376 |
|
| 1999 |
Harkin A, Kelly JP, McNamara M, Connor TJ, Dredge K, Redmond A, Leonard BE. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. European Journal of Pharmacology. 364: 123-32. PMID 9932714 DOI: 10.1016/S0014-2999(98)00838-3 |
0.402 |
|
| 1999 |
Harkin A, Naughton M, Cryan J, Kelly J, Leonard B. Differential modification of d-fenfluramine-induced serotonergic responses by acute and chronic sertraline and fluoxetine administration to rats European Neuropsychopharmacology. 9: 242. DOI: 10.1016/S0924-977X(99)80211-9 |
0.311 |
|
| Show low-probability matches. |